Skip to main content
. 2018 Aug 1;7(10):e1484982. doi: 10.1080/2162402X.2018.1484982

Figure 8.

Figure 8.

SGT-53 prevents fatal xenogeneic hypersensitivity following repeated anti-PD1 administration in a syngeneic 4T1 breast cancer model. (A) Survival of BALB/c mice bearing 4T1 tumor after repeated dosing with anti-PD1 antibody alone or in combination with SGT-53. Mice received total five injections of SGT-53 and/or five injections of anti-PD1 following the treatment schedule shown in Figure 3A. Arrows indicate the anti-PD1 injection. (B) Representative H&E stains of lungs and livers of mice treated with either anti-PD1 alone or in combination with SGT-53. Arrowheads indicate neutrophilic accumulation. Scale bars, 200 µm. (C) Infiltrating neutrophils (CD11b+F4/80−Gr1hi) and macrophages (CD11b+F4/80+) were assayed in the lung via FACS (n = 4). Infiltrating cells are shown in absolute number of cells per 1 × 104 live cells collected. (D) Heatmap of significantly altered gene expression in tumor tissue from mice treated with anti-PD1 antibody that were reversed in tumor tissue from mice treated with anti-PD1 plus SGT-53. (E) Sera from tumor bearing mice receiving the indicated treatment were collected and analyzed for levels of mouse GM-CSF or TNFα using ELISA (n = 8). Data are shown as mean ± SEM. *p < 0.05, **p < 0.001, 1-way ANOVA with Bonferroni t-test.